Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 May 30:5:55.
doi: 10.1186/1471-2407-5-55.

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

Dirk Vordermark  1 , Oliver Kölbl, Klemens Ruprecht, Giles H Vince, Klaus Bratengeier, Michael Flentje
Affiliations

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

Dirk Vordermark et al. BMC Cancer. .

Abstract

Background: Hypofractionated stereotactic radiotherapy (HFSRT) is one salvage treatment option in previously irradiated patients with recurrent malignant glioma. We analyzed the results of HFSRT and prognostic factors in a single-institution series.

Methods: Between 1997 and 2003, 19 patients with recurrent malignant glioma (14 glioblastoma on most recent histology, 5 anaplastic astrocytoma) were treated with HFSRT. The median interval from post-operative radiotherapy to HFSRT was 19 (range 3-116) months, the median daily single dose 5 (4-10) Gy, the median total dose 30 (20-30) Gy and the median planning target volume 15 (4-70) ml.

Results: The median overall survival (OS) was 9.3 (1.9-77.6+) months from the time of HFSRT, 15.4 months for grade III and 7.9 months for grade IV tumors (p = 0.029, log-rank test). Two patients were alive at 34.6 and 77.6 months. OS was longer after a total dose of 30 Gy (11.1 months) than after total doses of <30 Gy (7.4 months; p = 0.051). Of five (26%) reoperations, none was performed for presumed or histologically predominant radiation necrosis. Median time to tumor progression after HFSRT on imaging was 4.9 months (1.3 to 37.3) months.

Conclusion: HFSRT with conservative total doses of no more than 30 Gy is safe and leads to similar OS times as more aggressive treatment schemes. In individual patients, HFSRT in combination with other salvage treatment modalities, was associated with long-term survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival of n = 19 patients with recurrent malignant glioma treated with hypofractionated stereotactic radiotherapy (HFSRT), from the time of re-irradiation.
Figure 2
Figure 2
Overall survival from the time of re-irradiation of n = 19 patients with recurrent malignant glioma treated with hypofractionated stereotactic radiotherapy (HFSRT), by WHO grade (most recent histopathology before HFSRT).
Figure 3
Figure 3
Overall survival from the time of re-irradiation of n = 19 patients with recurrent malignant glioma treated with hypofractionated stereotactic radiotherapy (HFSRT), by total dose.
See this image and copyright information in PMC

References

    1. Oppitz U, Maessen D, Zunterer H, Richter S, Flentje M. 3-D recurrence patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol. 1999;53:53–57. doi: 10.1016/S0167-8140(99)00117-6. - DOI - PubMed
    1. Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999;45:1133–1141. doi: 10.1016/S0360-3016(99)00336-3. - DOI - PubMed
    1. van Kampen M, Engenhart-Cabilic R, Debus J, Fuß M, Rhein B, Wannenmacher M. The value of radiosurgery for recurrent glioblastoma multiforme (German) The Heidelberg experience and review of the literature Strahlenther Onkol. 1998;174:19–24. - PubMed
    1. Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997;37:393–398. doi: 10.1016/S0360-3016(96)00455-5. - DOI - PubMed
    1. Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 1999;43:291–298. doi: 10.1016/S0360-3016(98)00416-7. - DOI - PubMed

MeSH terms